Neurofibroma, Plexiform
Conditions
Brief summary
The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD
Interventions
DRUGImatinib Mesylate
Imatinib given orally as dose escalation treatment.
Sponsors
Indiana University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged: \> 6 months and \< 12 years of age. 2. Diagnosis of neurofibromatosis type 1 (NF1). 3. Presence of symptomatic airway plexiform neurofibromas ; defined by abnormal sleep study or pulmonary function testing. 4. Patients must have measurable (\> 1.5 cm in two dimensions or able to assess a minimum of 3 slices) disease by magnetic resonance imaging (MRI). 5. Patients must have a Karnofsky of \> 70% or Lansky of \> 50% and a life expectancy of \> 2 months. 6. Adequate end organ function, defined as the following: total bilirubin \< 1.5 x ULN, SGOT and SGPT \< 2.5 x UNL, creatinine \< 1.5 x ULN, ANC \> 1.5 x 109/L, platelets \> 100 x 109/L. 7. Patients must be able to swallow whole pills or crushed pills in a soft food such as pudding or apple sauce; or have other GI access such as a G-tube. 8. Written, voluntary informed consent/assent.
Exclusion criteria
1. Patient has received any other investigational agents within 14 days of first day of study drug dosing. 2. Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed. 3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study) 4. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection). 5. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies requiring therapeutic intervention. 6. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis). 7. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. 8. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry. 9. Patient previously received radiotherapy to \> 25 % of the bone marrow 10. Patient had a major surgery within 2 weeks prior to study entry. 11. Patient/parent with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent. 12. Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI. 13. Patient has an unstable airway requiring more urgent intervention or deemed unable to travel due to unstable airway by referring MD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantitative Functional Airway Response | 12 months | Sleep study or pulmonary function test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiologic response of tumor | 12 months | Volumetric MRI measurements |
| Quality of Life Assessment | 12 months | Quality of Life Questionnaire |
| Cytokine Biomarker | 12 months | Immunoassay |
| Inflammatory Cell Biomarker | 12 months | Flow cytometry |
Countries
United States
Outcome results
None listed